Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread

Acta Neurochir (Wien). 2018 May;160(5):1073-1077. doi: 10.1007/s00701-018-3509-9. Epub 2018 Mar 13.

Abstract

Leptomeningeal spread and hydrocephalus are increasingly recognized as late disease complications of glioblastoma with almost a quarter of patients requiring early cerebrospinal fluid shunting. The neurosurgeon is challenged with maintaining shunt patency when tumor disease progression is rapid and adjuvant oncologic therapy has yet to be initiated. We describe our experience in treating a young female with diffuse glioblastoma leptomeningeal spread and communicating hydrocephalus who had several episodes of shunt obstruction due to intraluminal tumor cell-fibrin deposits. Regular intraventricular instillations of urokinase fibrinolytic therapy not only re-established shunt patency but also contributed to the resolution of her hydrocephalus.

Keywords: Fibrinolytic; Glioblastoma; Hydrocephalus; Leptomeningeal spread; Urokinase.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Glioblastoma / surgery*
  • Humans
  • Hydrocephalus / surgery*
  • Meninges
  • Neurosurgical Procedures / adverse effects
  • Prostheses and Implants / adverse effects
  • Thrombolytic Therapy*
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Ventriculoperitoneal Shunt / adverse effects*
  • Young Adult

Substances

  • Urokinase-Type Plasminogen Activator